Search

Your search keyword '"Weusten, Bas L.A.M."' showing total 217 results
Start Over Author "Weusten, Bas L.A.M."
217 results on '"Weusten, Bas L.A.M."'

1. Computer-aided diagnosis improves characterization of Barrett’s neoplasia by general endoscopists (with video)

Author

Alkhalaf, Alaa, Herrero, Lorenza Alvarez, Baldaque-Silva, Francisco, Barret, Maximilien, Bergman, Jacques J., Beyna, Torsten, Bisschops, Raf, Boers, Tim G., Curvers, Wouter, Deprez, Pierre H., Duits, Lucas C., Elbe, Peter, Esteban, Jose Miguel, Falk, Gary W., Fockens, Kiki N., Ginsberg, Gregory G., de Groof, Albert J., Haidry, Rehan, Houben, Martin H., Infantolino, Anthony, Iyer, Prasad G., Jong, Martijn, Jonge, Pieter-Jan de, Jukema, Jelmer B., Koch, Arjun, Komanduri, Srinadh, Konda, Vani, Kusters, Koen C., Leclerq, Philippe, Leggett, Cadman L., Lightdale, Charles J., Mallant-Hent, Rosalie C., Villarejo, Guiomar Moral, Fernández-Sordo, Jacobo Ortiz, Pech, Oliver, Penman, Ian, Pouw, Roos E., van der Putten, Joost A., Ragunath, Krish, Scholten, Pieter, Seewald, Stefan, Sethi, Amritha, Smith, Michael S., van der Sommen, Fons, Trindade, Arvind, Wani, Sachin, Waxman, Irving, Westerhof, Jessie, Weusten, Bas L., de With, Peter H., Wolfsen, Herbert C., Kusters, Carolus H.J., Jong, Martijn R., Boers, Tim, Weusten, Bas L.A.M., Houben, Martin H.M.G., Nagengast, Wouter B., Mallant-Hent, Rosalie, Silva, Francisco Baldaque, Ortiz Fernández-Sordo, Jacobo, Moral Villarejo, Guiomar, Montazeri, Nahid S.M., der Sommen, Fons van, and de Groof, A. Jeroen

Published
2024
Full Text
View/download PDF

2. Incidence and Prediction of Unrelated Mortality After Successful Endoscopic Eradication Therapy for Barrett’s Neoplasia

Author

van Munster, Sanne.N., Verheij, Eva P.D., Ozdemir, Özge, Toes-Zoutendijk, Esther, Lansdorp-Vogelaar, Iris, Nieuwenhuis, Esther A., Cotton, Cary C., Weusten, Bas L.A.M., Alvarez Herrero, Lorenza, Alkhalaf, Alaa, Schenk, B. Ed, Schoon, Erik J., Curvers, Wouter L., Koch, Arjun D., de Jonge, Pieter-Jan F., Tang, Thjon J., Nagengast, Wouter B., Westerhof, Jessie, Houben, Martin H.M.G., Shaheen, Nicholas J., Bergman, Jacques J.G.H.M., and Pouw, Roos E.

Published
2024
Full Text
View/download PDF

3. Western outcomes of circumferential endoscopic submucosal dissection for early esophageal squamous cell carcinoma

Author

Rodríguez de Santiago, Enrique, van Tilburg, Laurelle, Deprez, Pierre H., Pioche, Mathieu, Pouw, Roos E., Bourke, Michael J., Seewald, Stefan, Weusten, Bas L.A.M., Jacques, Jeremie, Leblanc, Sara, Barreiro, Pedro, Lemmers, Arnaud, Parra-Blanco, Adolfo, Küttner-Magalhães, Ricardo, Libânio, Diogo, Messmann, Helmut, Albéniz, Eduardo, Kaminski, Michal F., Mohammed, Noor, Ramos-Zabala, Felipe, Herreros-de-Tejada, Alberto, Huchima Koecklin, Hugo, Wallenhorst, Timothée, Santos-Antunes, João, Cunha Neves, João A., Koch, Arjun D., Ayari, Myriam, Garces-Duran, Rodrigo, Ponchon, Thierry, Rivory, Jérôme, Bergman, Jacques J.G.H.M., Verheij, Eva P.D., Gupta, Sunil, Groth, Stefan, Lepilliez, Vincent, Franco, Ana Rita, Belkhir, Sanaa, White, Jonathan, Ebigbo, Alanna, Probst, Andreas, Legros, Romain, Pilonis, Nastazja Dagny, de Frutos, Diego, Muñoz González, Raquel, and Dinis-Ribeiro, Mario

Published
2024
Full Text
View/download PDF

4. Clinical Relevance of Random Biopsies From the Esophagogastric Junction After Complete Eradication of Barrett’s Esophagus is Low

Author

Frederiks, Charlotte N., van Munster, Sanne N., Nieuwenhuis, Esther A., Alvarez Herrero, Lorenza, Alkhalaf, Alaa, Schenk, Boudewijn E., Schoon, Erik J., Curvers, Wouter L., Koch, Arjun D., de Jonge, Pieter-Jan F., Tang, Thjon, Nagengast, Wouter B., Westerhof, Jessie, Houben, Martin H.M.G., Bergman, Jacques J.G.H.M., Pouw, Roos E., and Weusten, Bas L.A.M.

Published
2023
Full Text
View/download PDF

5. Computer-aided diagnosis improves characterization of Barrett's neoplasia by general endoscopists (with video).

Author

Jukema, Jelmer B., Kusters, Carolus H.J., Jong, Martijn R., Fockens, Kiki N., Boers, Tim, van der Putten, Joost A., Pouw, Roos E., Duits, Lucas C., Weusten, Bas L.A.M., Herrero, Lorenza Alvarez, Houben, Martin H.M.G., Nagengast, Wouter B., Westerhof, Jessie, Alkhalaf, Alaa, Mallant-Hent, Rosalie, Scholten, Pieter, Ragunath, Krish, Seewald, Stefan, Elbe, Peter, and Silva, Francisco Baldaque

Abstract

Characterization of visible abnormalities in patients with Barrett's esophagus (BE) can be challenging, especially for inexperienced endoscopists. This results in suboptimal diagnostic accuracy and poor interobserver agreement. Computer-aided diagnosis (CADx) systems may assist endoscopists. We aimed to develop, validate, and benchmark a CADx system for BE neoplasia. The CADx system received pretraining with ImageNet and then consecutive domain-specific pretraining with GastroNet, which includes 5 million endoscopic images. It was subsequently trained and internally validated using 1758 narrow-band imaging (NBI) images of early BE neoplasia (352 patients) and 1838 NBI images of nondysplastic BE (173 patients) from 8 international centers. CADx was tested prospectively on corresponding image and video test sets with 30 cases (20 patients) of BE neoplasia and 60 cases (31 patients) of nondysplastic BE. The test set was benchmarked by 44 general endoscopists in 2 phases (phase 1, no CADx assistance; phase 2, with CADx assistance). Ten international BE experts provided additional benchmark performance. Stand-alone sensitivity and specificity of the CADx system were 100% and 98% for images and 93% and 96% for videos, respectively. CADx outperformed general endoscopists without CADx assistance in terms of sensitivity (P =.04). Sensitivity and specificity of general endoscopists increased from 84% to 96% and 90% to 98% with CAD assistance (P <.001). CADx assistance increased endoscopists' confidence in characterization (P <.001). CADx performance was similar to that of the BE experts. CADx assistance significantly increased characterization performance of BE neoplasia by general endoscopists to the level of expert endoscopists. The use of this CADx system may thereby improve daily Barrett surveillance. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Safety and efficacy of salvage endoscopic submucosal dissection for Barrett's neoplasia recurrence after radiofrequency ablation.

Author

Mesureur, Lauriane, Deprez, Pierre H., Bisschops, Raf, Pouw, Roos E., Weusten, Bas L.A.M., Barret, Maximilien, Dewint, Pieter, Tate, David, Leclercq, Philippe, Seewald, Stefan, Barbaro, Federico, Baldaque-Silva, Francisco, Omae, Masami, Pioche, Mathieu, Figueiredo Ferreira, Mariana, Bourke, Michael J., Haidry, Rehan, Snauwaert, Christophe, Eisendrath, Pierre, and De Maertelaer, Viviane

Subjects
ELECTROCOAGULATION (Medicine), BARRETT'S esophagus, ENDOSCOPIC surgery, CATHETER ablation, TUMORS
Abstract

Background This study evaluated the safety and efficacy of salvage endoscopic submucosal dissection (ESD) for Barrett's neoplasia recurrence after radiofrequency ablation (RFA). Methods Data from patients at 16 centers were collected for a multicenter retrospective study. Patients who underwent at least one RFA treatment for Barrett's esophagus and thereafter underwent further esophageal ESD for neoplasia recurrence were included. Results Data from 56 patients who underwent salvage ESD between April 2014 and November 2022 were collected. Immediate complications included one muscular tear (1.8%) treated with stent (Agree classification: grade IIIa). Two transmural perforations (3.6%; treated with clips) and five muscular tears (8.9%; two treated with clips) had no clinical impact and were not considered as adverse events. Seven patients (12.5%) developed strictures (grade IIIa), which were treated with balloon dilation. Histological analysis showed 36 adenocarcinoma, 17 high grade dysplasia, and 3 low grade dysplasia. En bloc and R0 resection rates were 89.3% and 66.1%, respectively. Resections were curative in 33 patients (58.9%), and noncurative in 22 patients (39.3%), including 11 "local risk" (19.6%) and 11 "high risk" (19.6%) resections. At the end of follow-up with a median time of 14 (0–75) months after salvage ESD, and with further endoscopic treatment if necessary (RFA, argon plasma coagulation, endoscopic mucosal resection, ESD), neoplasia remission ratio was 37/53 (69.8%) and the median remission time was 13 (1–75) months. Conclusion In expert hands, salvage ESD was a safe and effective treatment for recurrence of Barrett's neoplasia after RFA treatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Incidence and Prediction of Unrelated Mortality After Successful Endoscopic Eradication Therapy for Barrett's Neoplasia

Author

MS MDL 1, Cancer, van Munster, Sanne N., Verheij, Eva P.D., Ozdemir, Özge, Toes-Zoutendijk, Esther, Lansdorp-Vogelaar, Iris, Nieuwenhuis, Esther A., Cotton, Cary C., Weusten, Bas L.A.M., Alvarez Herrero, Lorenza, Alkhalaf, Alaa, Schenk, B. Ed, Schoon, Erik J., Curvers, Wouter L., Koch, Arjun D., de Jonge, Pieter Jan F., Tang, Thjon J., Nagengast, Wouter B., Westerhof, Jessie, Houben, Martin H.M.G., Shaheen, Nicholas J., Bergman, Jacques J.G.H.M., Pouw, Roos E., MS MDL 1, Cancer, van Munster, Sanne N., Verheij, Eva P.D., Ozdemir, Özge, Toes-Zoutendijk, Esther, Lansdorp-Vogelaar, Iris, Nieuwenhuis, Esther A., Cotton, Cary C., Weusten, Bas L.A.M., Alvarez Herrero, Lorenza, Alkhalaf, Alaa, Schenk, B. Ed, Schoon, Erik J., Curvers, Wouter L., Koch, Arjun D., de Jonge, Pieter Jan F., Tang, Thjon J., Nagengast, Wouter B., Westerhof, Jessie, Houben, Martin H.M.G., Shaheen, Nicholas J., Bergman, Jacques J.G.H.M., and Pouw, Roos E.

Published
2024

9. Western outcomes of circumferential endoscopic submucosal dissection for early esophageal squamous cell carcinoma

Author

MS MDL 1, Cancer, Rodríguez de Santiago, Enrique, van Tilburg, Laurelle, Deprez, Pierre H., Pioche, Mathieu, Pouw, Roos E., Bourke, Michael J., Seewald, Stefan, Weusten, Bas L.A.M., Jacques, Jeremie, Leblanc, Sara, Barreiro, Pedro, Lemmers, Arnaud, Parra-Blanco, Adolfo, Küttner-Magalhães, Ricardo, Libânio, Diogo, Messmann, Helmut, Albéniz, Eduardo, Kaminski, Michal F., Mohammed, Noor, Ramos-Zabala, Felipe, Herreros-de-Tejada, Alberto, Huchima Koecklin, Hugo, Wallenhorst, Timothée, Santos-Antunes, João, Cunha Neves, João A., Koch, Arjun D., Ayari, Myriam, Garces-Duran, Rodrigo, Ponchon, Thierry, Rivory, Jérôme, Bergman, Jacques J.G.H.M., Verheij, Eva P.D., Gupta, Sunil, Groth, Stefan, Lepilliez, Vincent, Franco, Ana Rita, Belkhir, Sanaa, White, Jonathan, Ebigbo, Alanna, Probst, Andreas, Legros, Romain, Pilonis, Nastazja Dagny, de Frutos, Diego, Muñoz González, Raquel, Dinis-Ribeiro, Mario, MS MDL 1, Cancer, Rodríguez de Santiago, Enrique, van Tilburg, Laurelle, Deprez, Pierre H., Pioche, Mathieu, Pouw, Roos E., Bourke, Michael J., Seewald, Stefan, Weusten, Bas L.A.M., Jacques, Jeremie, Leblanc, Sara, Barreiro, Pedro, Lemmers, Arnaud, Parra-Blanco, Adolfo, Küttner-Magalhães, Ricardo, Libânio, Diogo, Messmann, Helmut, Albéniz, Eduardo, Kaminski, Michal F., Mohammed, Noor, Ramos-Zabala, Felipe, Herreros-de-Tejada, Alberto, Huchima Koecklin, Hugo, Wallenhorst, Timothée, Santos-Antunes, João, Cunha Neves, João A., Koch, Arjun D., Ayari, Myriam, Garces-Duran, Rodrigo, Ponchon, Thierry, Rivory, Jérôme, Bergman, Jacques J.G.H.M., Verheij, Eva P.D., Gupta, Sunil, Groth, Stefan, Lepilliez, Vincent, Franco, Ana Rita, Belkhir, Sanaa, White, Jonathan, Ebigbo, Alanna, Probst, Andreas, Legros, Romain, Pilonis, Nastazja Dagny, de Frutos, Diego, Muñoz González, Raquel, and Dinis-Ribeiro, Mario

Published
2024

10. Vertical tumor-positive resection margins and the risk of residual neoplasia after endoscopic resection of Barrett's neoplasia:a nationwide cohort with pathology reassessment

Author

van Tilburg, Laurelle, Verheij, Eva P.D., van de Ven, Steffi E.M., van Munster, Sanne N., Weusten, Bas L.A.M., Herrero, Lorenza Alvarez, Nagengast, Wouter B., Schoon, Erik J., Alkhalaf, Alaa, Bergman, Jacques J.G.H.M., Pouw, Roos E., Oudijk, Lindsey, Meijer, Sybren L., Jansen, Marnix, Doukas, Michail, Koch, Arjun D., van Tilburg, Laurelle, Verheij, Eva P.D., van de Ven, Steffi E.M., van Munster, Sanne N., Weusten, Bas L.A.M., Herrero, Lorenza Alvarez, Nagengast, Wouter B., Schoon, Erik J., Alkhalaf, Alaa, Bergman, Jacques J.G.H.M., Pouw, Roos E., Oudijk, Lindsey, Meijer, Sybren L., Jansen, Marnix, Doukas, Michail, and Koch, Arjun D.

Abstract

BACKGROUND: This study evaluated the proportion of patients with residual neoplasia after endoscopic resection (ER) for Barrett's neoplasia with confirmed tumor-positive vertical resection margin (R1v). METHODS: This retrospective cohort study included patients undergoing ER for Barrett's neoplasia with histologically documented R1v since 2008 in the Dutch Barrett Expert Centers. We defined R1v as cancer cells touching vertical resection margins and Rx as nonassessable margins. Reassessment of R1v specimens was performed by experienced pathologists until consensus was reached regarding vertical margins. RESULTS: 101/110 included patients had macroscopically complete resections (17 T1a, 84 T1b), and 99/101 (98%) ER specimens were histologically reassessed, with R1v confirmed in 74 patients (75%), Rx in 16%, and R0 in 9%. Presence/absence of residual neoplasia could be assessed in 66/74 patients during endoscopic reassessment (52) and/or in the surgical resection specimen (14), and 33/66 (50%) had residual neoplasia. Residual neoplasia detected during endoscopy was always endoscopically visible and biopsies from a normal-appearing ER scar did not detect additional neoplasia. Of 25 patients who underwent endoscopic follow-up (median 37 months [interquartile range 12-50]), 4 developed local recurrence (16.0%), all detected as visible abnormalities. CONCLUSIONS: After ER with R1v, 50% of patients had no residual neoplasia. Histological evaluation of ER margins appears challenging, as in this study 75% of documented R1v cases were confirmed during reassessment. Endoscopic reassessment 8-12 weeks after ER seems to accurately detect residual neoplasia and can help to determine the most appropriate strategy for patients with R1v.

Published
2024

11. Incidence and Prediction of Unrelated Mortality After Successful Endoscopic Eradication Therapy for Barrett's Neoplasia

Author

van Munster, Sanne N., Verheij, Eva P.D., Ozdemir, Özge, Toes-Zoutendijk, Esther, Lansdorp-Vogelaar, Iris, Nieuwenhuis, Esther A., Cotton, Cary C., Weusten, Bas L.A.M., Alvarez Herrero, Lorenza, Alkhalaf, Alaa, Schenk, B. Ed, Schoon, Erik J., Curvers, Wouter L., Koch, Arjun D., de Jonge, Pieter Jan F., Tang, Thjon J., Nagengast, Wouter B., Westerhof, Jessie, Houben, Martin H.M.G., Shaheen, Nicholas J., Bergman, Jacques J.G.H.M., Pouw, Roos E., van Munster, Sanne N., Verheij, Eva P.D., Ozdemir, Özge, Toes-Zoutendijk, Esther, Lansdorp-Vogelaar, Iris, Nieuwenhuis, Esther A., Cotton, Cary C., Weusten, Bas L.A.M., Alvarez Herrero, Lorenza, Alkhalaf, Alaa, Schenk, B. Ed, Schoon, Erik J., Curvers, Wouter L., Koch, Arjun D., de Jonge, Pieter Jan F., Tang, Thjon J., Nagengast, Wouter B., Westerhof, Jessie, Houben, Martin H.M.G., Shaheen, Nicholas J., Bergman, Jacques J.G.H.M., and Pouw, Roos E.

Abstract

Background & Aims: Follow-up (FU) strategies after endoscopic eradication therapy (EET) for Barrett's neoplasia do not consider the risk of mortality from causes other than esophageal adenocarcinoma (EAC). We aimed to evaluate this risk during long-term FU, and to assess whether the Charlson Comorbidity Index (CCI) can predict mortality. Methods: We included all patients with successful EET from the nationwide Barrett registry in the Netherlands. Data were merged with National Statistics for accurate mortality data. We evaluated annual mortality rates (AMRs, per 1000 person-years) and standardized mortality ratio for other-cause mortality. Performance of the CCI was evaluated by discrimination and calibration. Results: We included 1154 patients with a mean age of 64 years (±9). During median 59 months (p25–p75 37–91; total 6375 person-years), 154 patients (13%) died from other causes than EAC (AMR, 24.1; 95% CI, 20.5–28.2), most commonly non-EAC cancers (n = 58), cardiovascular (n = 31), or pulmonary diseases (n = 26). Four patients died from recurrent EAC (AMR, 0.5; 95% CI, 0.1–1.4). Compared with the general Dutch population, mortality was significantly increased for patients in the lowest 3 age quartiles (ie, age <71 years). Validation of CCI in our population showed good discrimination (Concordance statistic, 0.78; 95% CI, 0.72–0.84) and fair calibration. Conclusion: The other-cause mortality risk after successful EET was more than 40 times higher (48; 95% CI, 15–99) than the risk of EAC-related mortality. Our findings reveal that younger post-EET patients exhibit a significantly reduced life expectancy when compared with the general population. Furthermore, they emphasize the strong predictive ability of CCI for long-term mortality after EET. This straightforward scoring system can inform decisions regarding personalized FU, including appropriate cessation timing.

Published
2024

20. Perspectives and awareness of endoscopy healthcare professionals on sustainable practices in gastrointestinal endoscopy: results of the LEAFGREEN survey.

Author

Cunha Neves, João A., Rodriguez de Santiago, Enrique, Pohl, Heiko, Lorenzo-Zúñiga, Vicente, Cunha, Miguel F., Voiosu, Andrei M., Römmele, Christoph, Penman, Douglas G., Albéniz, Eduardo, Siau, Keith, Donnelly, Leigh, Elli, Luca, Pioche, Mathieu, Beilenhoff, Ulrike, Arvanitakis, Marianna, Weusten, Bas L.A.M., Bisschops, Raf, Hassan, Cesare, Messmann, Helmut, and Gralnek, Ian M.

Subjects
SUSTAINABILITY, MEDICAL personnel, ENDOSCOPY, PROFESSIONALISM, PROFESSIONAL practice
Abstract

Background Gastrointestinal (GI) endoscopy is one of healthcare's main contributors to climate change. We aimed to assess healthcare professionals' attitudes and the perceived barriers to implementation of sustainable GI endoscopy. Methods The LEAFGREEN web-based survey was a cross-sectional study conducted by the European Society of Gastrointestinal Endoscopy (ESGE) Green Endoscopy Working Group. The questionnaire comprised 39 questions divided into five sections (respondent demographics; climate change and sustainability beliefs; waste and resource management; single-use endoscopes and accessories; education and research). The survey was available via email to all active members of the ESGE and the European Society of Gastroenterology and Endoscopy Nurses and Associates (ESGENA) in March 2023. Results 407 respondents participated in the survey (11% response rate). Most participants (86%) agreed climate change is real and anthropogenic, but one-third did not consider GI endoscopy to be a significant contributor to climate change. Improvement in the appropriateness of endoscopic procedures (41%) and reduction in single-use accessories (34%) were considered the most important strategies to reduce the environmental impact of GI endoscopy. Respondents deemed lack of institutional support and knowledge from staff to be the main barriers to sustainable endoscopy. Strategies to reduce unnecessary GI endoscopic procedures and comparative studies of single-use versus reusable accessories were identified as research priorities. Conclusions In this survey, ESGE and ESGENA members acknowledge climate change as a major threat to humanity. Further improvement in sustainability beliefs and professional attitudes, reduction in inappropriate GI endoscopy, and rational use of single-use accessories and endoscopes are critically required. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. The occurrence and characteristics of endoscopically unexpected malignant degeneration in large rectal adenomas

Author

Bemelman, Willem A., Bijnen, Bart, Bisschops, Raf, van den Broek, Frank J.C., Davids, Paul, Depla, Annekatrien, van Dullemen, Hendrik, Hardwick, James C., Hoff, Chrisiaan, Houben, Martin, Jansen, Jeroen M., Gerhards, Michael F., van der Linde, Klaas, van Milligen de Wit, A.W. Marc, Mallant, Rosalie, van der Schelling, George P., Timmer, Robin, Witteman, Ben, Weusten, Bas L.A.M., Wolthuis, Albert, Bronzwaer, Maxime E.S., Musters, Gijsbert D., Barendse, Renée M., Koens, Lianne, de Graaf, Eelco J.R., Doornebosch, Pascal G., Schwartz, Matthijs P., Consten, Esther C.J., Schoon, Erik J., de Hingh, Ignace H.J.T., Tanis, Pieter J., Dekker, Evelien, and Fockens, Paul

Published
2018
Full Text
View/download PDF

25. Endoscopic submucosal dissection techniques and technology: European Society of Gastrointestinal Endoscopy (ESGE) Technical Review

Author

Libânio, Diogo, primary, Pimentel-Nunes, Pedro, primary, Bastiaansen, Barbara, additional, Bisschops, Raf, additional, Bourke, Michael J., additional, Deprez, Pierre H., additional, Esposito, Gianluca, additional, Lemmers, Arnaud, additional, Leclercq, Philippe, additional, Maselli, Roberta, additional, Messmann, Helmut, additional, Pech, Oliver, additional, Pioche, Mathieu, additional, Vieth, Michael, additional, Weusten, Bas L.A.M., additional, Fuccio, Lorenzo, additional, Bhandari, Pradeep, additional, and Dinis-Ribeiro, Mario, additional

Published
2023
Full Text
View/download PDF

26. Diagnosis and management of Barrett esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Guideline

Author

MS MDL 1, Cancer, Weusten, Bas L.A.M., Bisschops, Raf, Dinis-Ribeiro, Mario, Di Pietro, Massimiliano, Pech, Oliver, Spaander, Manon C.W., Baldaque-Silva, Francisco, Barret, Maximilien, Coron, Emmanuel, Fernández-Esparrach, Glòria, Fitzgerald, Rebecca C., Jansen, Marnix, Jovani, Manol, Marques-De-Sa, Ines, Rattan, Arti, Tan, W. Keith, Verheij, Eva P.D., Zellenrath, Pauline A., Triantafyllou, Konstantinos, Pouw, Roos E., MS MDL 1, Cancer, Weusten, Bas L.A.M., Bisschops, Raf, Dinis-Ribeiro, Mario, Di Pietro, Massimiliano, Pech, Oliver, Spaander, Manon C.W., Baldaque-Silva, Francisco, Barret, Maximilien, Coron, Emmanuel, Fernández-Esparrach, Glòria, Fitzgerald, Rebecca C., Jansen, Marnix, Jovani, Manol, Marques-De-Sa, Ines, Rattan, Arti, Tan, W. Keith, Verheij, Eva P.D., Zellenrath, Pauline A., Triantafyllou, Konstantinos, and Pouw, Roos E.

Published
2023

27. Towards a robust and compact deep learning system for primary detection of early Barrett’s neoplasia: Initial image-based results of training on a multi-center retrospectively collected data set

Author

MS MDL 1, Cancer, Fockens, Kiki N., Jukema, Jelmer B., Boers, Tim, Jong, Martijn R., van der Putten, Joost A., Pouw, Roos E., Weusten, Bas L.A.M., Alvarez Herrero, Lorenza, Houben, Martin H.M.G., Nagengast, Wouter B., Westerhof, Jessie, Alkhalaf, Alaa, Mallant, Rosalie, Ragunath, Krish, Seewald, Stefan, Elbe, Peter, Barret, Maximilien, Ortiz Fernández-Sordo, Jacobo, Pech, Oliver, Beyna, Torsten, van der Sommen, Fons, de With, Peter H., de Groof, A. Jeroen, Bergman, Jacques J., MS MDL 1, Cancer, Fockens, Kiki N., Jukema, Jelmer B., Boers, Tim, Jong, Martijn R., van der Putten, Joost A., Pouw, Roos E., Weusten, Bas L.A.M., Alvarez Herrero, Lorenza, Houben, Martin H.M.G., Nagengast, Wouter B., Westerhof, Jessie, Alkhalaf, Alaa, Mallant, Rosalie, Ragunath, Krish, Seewald, Stefan, Elbe, Peter, Barret, Maximilien, Ortiz Fernández-Sordo, Jacobo, Pech, Oliver, Beyna, Torsten, van der Sommen, Fons, de With, Peter H., de Groof, A. Jeroen, and Bergman, Jacques J.

Published
2023

28. Pelvic insufficiency fractures and pelvic bone metastases after neoadjuvant (chemo)radiotherapy for rectal cancer

Author

MS MDL 1, Cancer, MS Radiotherapie, Rijpma-Jacobs, Lotte, van der Vlies, Ellen, Meek, David B., Bollen, Thomas L., Siersema, Peter D., Weusten, Bas L.A.M., Intven, Martijn, van Lelyveld, Niels, Los, Maartje, MS MDL 1, Cancer, MS Radiotherapie, Rijpma-Jacobs, Lotte, van der Vlies, Ellen, Meek, David B., Bollen, Thomas L., Siersema, Peter D., Weusten, Bas L.A.M., Intven, Martijn, van Lelyveld, Niels, and Los, Maartje

Published
2023

29. The course of pain and dysphagia after radiofrequency ablation for Barrett's esophagus-related neoplasia

Author

MS MDL 1, Cancer, Epi Kanker Team C, JC onderzoeksprogramma Kanker, Overwater, Anouk, Elias, Sjoerd G., Schoon, Erik J., Bergman, Jacques J.G.H.M., Pouw, Roos E., Weusten, Bas L.A.M., MS MDL 1, Cancer, Epi Kanker Team C, JC onderzoeksprogramma Kanker, Overwater, Anouk, Elias, Sjoerd G., Schoon, Erik J., Bergman, Jacques J.G.H.M., Pouw, Roos E., and Weusten, Bas L.A.M.

Published
2023

30. Endoscopic Corticosteroid Injections Do Not Reduce Dysphagia After Endoscopic Dilation Therapy in Patients With Benign Esophagogastric Anastomotic Strictures

Author

Hirdes, Meike M.C., van Hooft, Jeanin E., Koornstra, Jan J., Timmer, Robin, Leenders, Max, Weersma, Rinse K., Weusten, Bas L.A.M., van Hillegersberg, Richard, van Berge Henegouwen, Mark I., Plukker, John T.M., Wiezer, Renee, Bergman, Jaques G.H.M., Vleggaar, Frank P., Fockens, Paul, and Siersema, Peter D.

Published
2013
Full Text
View/download PDF

31. Circumferential Balloon-based Radiofrequency Ablation of Barrett's Esophagus With Dysplasia Can Be Simplified, yet Efficacy Maintained, by Omitting the Cleaning Phase

Author

van Vilsteren, Frederike G.I., Phoa, K. Nadine, Alvarez Herrero, Lorenza, Pouw, Roos E., Sondermeijer, Carine M.T., van Lijnschoten, Ineke, Seldenrijk, Kees A., Visser, Mike, Meijer, Sybren L., van Berge Henegouwen, Mark I., Weusten, Bas L.A.M., Schoon, Erik J., and Bergman, Jacques J.G.H.M.

Published
2013
Full Text
View/download PDF

32. Analysis of metastases rates during follow-up after endoscopic resection of early “high-risk” esophageal adenocarcinoma

Author

Nieuwenhuis, Esther A., van Munster, Sanne N., Meijer, Sybren L., Brosens, L., Jansen, Marnix, Weusten, Bas L.A.M., Alvarez Herrero, Lorenza, Alkhalaf, Alaa, Schenk, Ed, Schoon, Erik J., Curvers, Wouter L., Koch, Arjun D., van de Ven, Steffi E.M., Verheij, Eva P.D., Nagengast, Wouter B., Westerhof, Jessie, Houben, Martin H.M.G., Tang, Thjon, Bergman, Jacques J.G.H.M., Pouw, Roos E., Meijer, S., Doukas, M., Nieuwenhuis, Esther A., van Munster, Sanne N., Meijer, Sybren L., Brosens, L., Jansen, Marnix, Weusten, Bas L.A.M., Alvarez Herrero, Lorenza, Alkhalaf, Alaa, Schenk, Ed, Schoon, Erik J., Curvers, Wouter L., Koch, Arjun D., van de Ven, Steffi E.M., Verheij, Eva P.D., Nagengast, Wouter B., Westerhof, Jessie, Houben, Martin H.M.G., Tang, Thjon, Bergman, Jacques J.G.H.M., Pouw, Roos E., Meijer, S., and Doukas, M.

Abstract

Background and Aims: After endoscopic resection (ER) of early esophageal adenocarcinoma (EAC), the optimal management of patients with high-risk histologic features for lymph node metastases (ie, submucosal invasion, poor differentiation grade, or lymphovascular invasion) remains unclear. We aimed to evaluate outcomes of endoscopic follow-up after ER for high-risk EAC. Methods: For this retrospective cohort study, data were collected from all Dutch patients managed with endoscopic follow-up (endoscopy, EUS) after ER for high-risk EAC between 2008 and 2019. We distinguished 3 groups: intramucosal cancers with high-risk features, submucosal cancers with low-risk features, and submucosal cancers with high-risk features. The primary outcome was the annual risk for metastases during follow-up, stratified for baseline histology. Results: One hundred twenty patients met the selection criteria. Median follow-up was 29 months (interquartile range, 15-48). Metastases were observed in 5 of 25 (annual risk, 6.9%; 95% confidence interval [CI], 3.0-15) high-risk intramucosal cancers, 1 of 55 (annual risk, .7%; 95% CI, 0-4.0) low-risk submucosal cancers, and 3 of 40 (annual risk, 3.0%; 95% CI, 0-7.0) high-risk submucosal cancers. Conclusions: Whereas the annual metastasis rate for high-risk submucosal EAC (3.0%) was somewhat lower than expected in comparison with previous reported percentages, the annual metastasis rate of 6.9% for high-risk intramucosal EAC is new and worrisome. This calls for further prospective studies and suggests that strict follow-up of this small subgroup is warranted until prospective data are available.

Published
2022

33. Extending treatment criteria for Barrett's neoplasia:Results of a nationwide cohort of 138 endoscopic submucosal dissection procedures

Author

Van Munster, Sanne N., Verheij, Eva P.D., Nieuwenhuis, Esther A., Offerhaus, Johan G.J.A., Meijer, Sybren L., Brosens, Lodewijk A.A., Weusten, Bas L.A.M., Alkhalaf, Alaa, Schenk, Ed B.E., Schoon, Erik J., Curvers, Wouter L., Van Tilburg, Laurelle, Van De Ven, Steffi E.M., Tang, Thjon J., Nagengast, Wouter B., Houben, Martin H.M.G., Seldenrijk, Kees C.A., Bergman, Jacques J.G.H.M., Koch, Arjun D., Pouw, Roos E., Van Munster, Sanne N., Verheij, Eva P.D., Nieuwenhuis, Esther A., Offerhaus, Johan G.J.A., Meijer, Sybren L., Brosens, Lodewijk A.A., Weusten, Bas L.A.M., Alkhalaf, Alaa, Schenk, Ed B.E., Schoon, Erik J., Curvers, Wouter L., Van Tilburg, Laurelle, Van De Ven, Steffi E.M., Tang, Thjon J., Nagengast, Wouter B., Houben, Martin H.M.G., Seldenrijk, Kees C.A., Bergman, Jacques J.G.H.M., Koch, Arjun D., and Pouw, Roos E.

Abstract

Background The use of endoscopic submucosal dissection (ESD) is gradually expanding for treatment of neoplasia in Barrett s esophagus (BE). We aimed to report outcomes of all ESDs for BE neoplasia performed in the Netherlands. Methods Retrospective assessment of outcomes, using treatment and follow-up data from a joint database. Results 130/138 patients had complete ESDs, with 126/ 130 (97%) en bloc resections. Median (interquartile range (IQR)) procedure time was 121 minutes (90 180). Pathology findings were high grade dysplasia (HGD) (5 %) or esophageal adenocarcinoma (EAC) T1a (43 %) or T1b (52%; 19% sm1, 33%≤sm2). Among resections of HGD or T1a EAC lesions, 87% (95%CI 75% 92 %) were both en bloc and R0; the corresponding value for T1b EAC lesions was 49% (36% 60 %). Among R1 resections, 10/34 (29%) showed residual cancer, all detected at first endoscopic follow-up. The remaining 24 patients (71 %) showed no residual neoplasia. Six of these patients underwent surgery with no residual tumor; the remaining 18 underwent endoscopic follow-up during median 31 months with 1 local recurrence (annual recurrence rate 2 %). Among R0 resections, annual local recurrence rate during median 27 months was 0.5 %. Conclusion In expert hands, ESD allows safe removal of bulky intraluminal neoplasia and submucosal cancer. ESD of the latter showed R1 resection margins in 50%, yet only one third had persisting neoplasia at follow-up. To better stratify R1 patients with an indication for additional surgery, repeat endoscopy after healing of the ESD might be a helpful possible prognostic factor for residual cancer.

Published
2022

34. Development and External Validation of a Model to Predict Complex Treatment After Radiofrequency Ablation for Barrett's Esophagus With Early Neoplasia

Author

van Munster, Sanne N., Nieuwenhuis, Esther, Bisschops, Raf, Willekens, Hilde, Weusten, Bas L.A.M., Herrero, Lorenza Alvarez, Bogte, Auke, Alkhalaf, Alaa, Schenk, Ed B.E., Schoon, Erik J., Curvers, Wouter, Koch, Arjun D., de Jonge, Pieter Jan F., Tang, Tjon J., Nagengast, Wouter B., Westerhof, Jessie, Houben, Martin H.M.G., Bergman, Jacques J.G.H.M., Pouw, Roos E., van Munster, Sanne N., Nieuwenhuis, Esther, Bisschops, Raf, Willekens, Hilde, Weusten, Bas L.A.M., Herrero, Lorenza Alvarez, Bogte, Auke, Alkhalaf, Alaa, Schenk, Ed B.E., Schoon, Erik J., Curvers, Wouter, Koch, Arjun D., de Jonge, Pieter Jan F., Tang, Tjon J., Nagengast, Wouter B., Westerhof, Jessie, Houben, Martin H.M.G., Bergman, Jacques J.G.H.M., and Pouw, Roos E.

Abstract

Background & Aims: Endoscopic eradication therapy for Barrett's esophagus (BE)-related neoplasia is safe and leads to complete eradication in the majority of patients. However, a subgroup will experience a more complex treatment course with a risk for failure or disease progression. Early identification of these patients may improve patient counseling and treatment outcomes. We aimed to develop a prognostic model for a complex treatment course. Methods: We collected data from a nationwide registry that captures outcomes for all patients undergoing endoscopic eradication therapy for early BE neoplasia. A complex treatment course was defined as neoplastic progression, treatment failure, or the need for endoscopic resection during the radiofrequency ablation treatment phase. We developed a prognostic model using logistic regression. We externally validated our model in an independent registry. Results: A total of 1386 patients were included, of whom 78 (6%) had a complex treatment course. Our model identified patients with a BE length of 9 cm or longer with a visible lesion containing high-grade dysplasia/cancer, and patients with less than 50% squamous conversion after radiofrequency ablation were identified as high risk for a complex treatment. This applied to 8% of the study population and included 93% of all treatment failures and 76% of all patients with advanced neoplastic progression. The model appeared robust in multiple sensitivity analyses and performed well in external validation (area under the curve, 0.84). Conclusions: We developed a prognostic model that identified patients with a BE length of 9 cm or longer and high-grade dysplasia/esophageal adenocarcinoma and those with poor squamous regeneration as high risk for a complex treatment course. The good performance in external validation suggests that it may be used in clinical management (Netherlands Trial Register: NL7039).

Published
2022

35. Impact of expert center endoscopic assessment of confirmed low grade dysplasia in Barrett's esophagus diagnosed in community hospitals

Author

Nieuwenhuis, Esther A., Van Munster, Sanne N., Curvers, Wouter L., Weusten, Bas L.A.M., Alvarez Herrero, Lorenza, Bogte, Auke, Alkhalaf, Alaa, Schenk, B. Ed, Koch, Arjun D., Spaander, Manon C.W., Tang, Thjon J., Nagengast, Wouter B., Westerhof, Jessie, Houben, Martin H.M.G., Bergman, Jacques J.G.H.M., Schoon, Erik J., Pouw, Roos E., Nieuwenhuis, Esther A., Van Munster, Sanne N., Curvers, Wouter L., Weusten, Bas L.A.M., Alvarez Herrero, Lorenza, Bogte, Auke, Alkhalaf, Alaa, Schenk, B. Ed, Koch, Arjun D., Spaander, Manon C.W., Tang, Thjon J., Nagengast, Wouter B., Westerhof, Jessie, Houben, Martin H.M.G., Bergman, Jacques J.G.H.M., Schoon, Erik J., and Pouw, Roos E.

Abstract

Background The optimal management for patients with low grade dysplasia (LGD) in Barrett’s esophagus (BE) is unclear. According to the Dutch national guideline, all patients with LGD with histological confirmation of the diagnosis by an expert pathologist (i. e. “confirmed LGD”), are referred for a dedicated re-staging endoscopy at an expert center. We aimed to assess the diagnostic value of re-staging endoscopy by an expert endoscopist for patients with confirmed LGD. Methods This retrospective cohort study included all patients with flat BE diagnosed in a community hospital who had confirmed LGD and were referred to one of the nine Barrett Expert Centers (BECs) in the Netherlands. The primary outcome was the proportion of patients with prevalent high grade dysplasia (HGD) or cancer during re-staging in a BEC. Results Of the 248 patients with confirmed LGD, re-staging in the BEC revealed HGD or cancer in 23% (57/248). In 79% (45/57), HGD or cancer in a newly detected visible lesion was diagnosed. Of the remaining patients, re-staging in the BEC showed a second diagnosis of confirmed LGD in 68% (168/248), while the remaining 9% (23/248) had nondysplastic BE. Conclusion One quarter of patients with apparent flat BE with confirmed LGD diagnosed in a community hospital had prevalent HGD or cancer after re-staging at an expert center. This endorses the advice to refer patients with confirmed LGD, including in the absence of visible lesions, to an expert center for re-staging endoscopy.

Published
2022

36. Dysplastic Recurrence After Successful Treatment for Early Barrett's Neoplasia:Development and Validation of a Prediction Model

Author

van Munster, Sanne N., Nieuwenhuis, Esther, Bisschops, Raf, Willekens, Hilde, Weusten, Bas L.A.M., Herrero, Lorenza Alvarez, Bogte, Auke, Alkhalaf, Alaa, Schenk, Ed B.E., Schoon, Erik J., Curvers, Wouter, Koch, Arjun D., de Jonge, Pieter Jan F., Tang, Tjon J., Nagengast, Wouter B., Westerhof, Jessie, Houben, Martin H.M.G., Seewald, Stefan, Eijkemans, Martinus J.C., Bergman, Jacques J.G.H.M., Pouw, Roos E., van Munster, Sanne N., Nieuwenhuis, Esther, Bisschops, Raf, Willekens, Hilde, Weusten, Bas L.A.M., Herrero, Lorenza Alvarez, Bogte, Auke, Alkhalaf, Alaa, Schenk, Ed B.E., Schoon, Erik J., Curvers, Wouter, Koch, Arjun D., de Jonge, Pieter Jan F., Tang, Tjon J., Nagengast, Wouter B., Westerhof, Jessie, Houben, Martin H.M.G., Seewald, Stefan, Eijkemans, Martinus J.C., Bergman, Jacques J.G.H.M., and Pouw, Roos E.

Abstract

Background & Aims: The combination of endoscopic resection and radiofrequency ablation is the treatment of choice for eradication of Barrett's esophagus (BE) with dysplasia and/or early cancer. Currently, there are no evidence-based recommendations on how to survey patients after successful treatment, and most patients undergo frequent follow-up endoscopies. We aimed to develop and externally validate a prediction model for visible dysplastic recurrence, which can be used to personalize surveillance after treatment. Methods: We collected data from the Dutch Barrett Expert Center Registry, a nationwide registry that captures outcomes from all patients with BE undergoing endoscopic treatment in the Netherlands in a centralized care setting. We used predictors related to demographics, severity of reflux, histologic status at baseline, and treatment characteristics. We built a Fine and Gray survival model with least absolute shrinkage and selection operator penalization to predict the incidence of visible dysplastic recurrence after initial successful treatment. The model was validated externally in patients with BE treated in Switzerland and Belgium. Results: A total of 1154 patients with complete BE eradication were included for model building. During a mean endoscopic follow-up of 4 years, 38 patients developed recurrent disease (1.0%/person-year). The following characteristics were independently associated with recurrence (strongest to weakest predictor): a new visible lesion during treatment phase, higher number of endoscopic resection treatments, male sex, increasing BE length, high-grade dysplasia or cancer at baseline, and younger age. External validation showed a C-statistic of 0.91 (95% confidence interval, 0.86–0.94) with good calibration. Conclusions: This is the first externally validated model to predict visible dysplastic recurrence after successful endoscopic eradication treatment of BE with dysplasia or early cancer. On external validation, our m

Published
2022

37. Long-term outcomes after endoscopic treatment for Barrett's neoplasia with radiofrequency ablation ± endoscopic resection:Results from the national Dutch database in a 10-year period

Author

Van Munster, Sanne, Nieuwenhuis, Esther, Weusten, Bas L.A.M., Alvarez Herrero, Lorenza, Bogte, Auke, Alkhalaf, Alaa, Schenk, B. E., Schoon, Erik J., Curvers, Wouter, Koch, Arjun D., Van De Ven, Steffi Elisabeth Maria, De Jonge, Pieter Jan Floris, Tang, Tjon J., Nagengast, Wouter B., Peters, Frans T.M., Westerhof, Jessie, Houben, Martin H.M.G., Bergman, Jacques Jghm, Pouw, Roos E., Van Munster, Sanne, Nieuwenhuis, Esther, Weusten, Bas L.A.M., Alvarez Herrero, Lorenza, Bogte, Auke, Alkhalaf, Alaa, Schenk, B. E., Schoon, Erik J., Curvers, Wouter, Koch, Arjun D., Van De Ven, Steffi Elisabeth Maria, De Jonge, Pieter Jan Floris, Tang, Tjon J., Nagengast, Wouter B., Peters, Frans T.M., Westerhof, Jessie, Houben, Martin H.M.G., Bergman, Jacques Jghm, and Pouw, Roos E.

Abstract

Objective Radiofrequency ablation (RFA)±endoscopic resection (ER) is the preferred treatment for early neoplasia in Barrett's oesophagus (BE). We aimed to report short-term and long-term outcomes for all 1384 patients treated in the Netherlands (NL) from 2008 to 2018, with uniform treatment and follow-up (FU) in a centralised setting. Design Endoscopic therapy for early BE neoplasia in NL is centralised in nine expert centres with specifically trained endoscopists and pathologists that adhere to a joint protocol. Prospectively collected data are registered in a uniform database. Patients with low/high-grade dysplasia or low-risk cancer, were treated by ER of visible lesions followed by trimonthly RFA sessions of any residual BE until complete eradication of BE (CE-BE). Patients with ER alone were not included. Results After ER (62% of cases; 43% low-risk cancers) and median 1 circumferential and 2 focal RFA (p25-p75 0-1; 1-2) per patient, CE-BE was achieved in 94% (1270/1348). Adverse events occurred in 21% (268/1386), most commonly oesophageal stenosis (15%), all were managed endoscopically. A total of 1154 patients with CE-BE were analysed for long-term outcomes. During median 43 months (22-69) and 4 endoscopies (1-5), 38 patients developed dysplastic recurrence (3%, annual recurrence risk 1%), all were detected as endoscopically visible abnormalities. Random biopsies from a normal appearing cardia showed intestinal metaplasia (IM) in 14% and neoplasia in 0%. A finding of IM in the cardia was reproduced during further FU in only 33%, none progressed to neoplasia. Frequent FU visits in the first year of FU were not associated with recurrence risk. Conclusion In a setting of centralised care, RFA±ER is effective for eradication of Barrett's related neoplasia and has remarkably low rates of dysplastic recurrence. Our data support more lenient FU intervals, with emphasis on careful endoscopic inspection. Random biopsies from neosquamous epithelium and cardia are of

Published
2022

38. Erratum: Impact of expert center endoscopic assessment of confirmed low grade dysplasia in Barrett's esophagus diagnosed in community hospitals (Endoscopy DOI: 10.1055/a-1754-7309)

Author

MS MDL 1, Cancer, Nieuwenhuis, Esther A., Van Munster, Sanne N., Curvers, Wouter L., Weusten, Bas L.A.M., Alvarez Herrero, Lorenza, Bogte, Auke, Alkhalaf, Alaa, Schenk, B. Ed, Koch, Arjun D., Spaander, Manon C.W., Tang, Thjon J., Nagengast, Wouter B., Westerhof, Jessie, Houben, Martin H.M.G., Bergman, Jacques J.G.H.M., Schoon, Erik J., Pouw, Roos E., MS MDL 1, Cancer, Nieuwenhuis, Esther A., Van Munster, Sanne N., Curvers, Wouter L., Weusten, Bas L.A.M., Alvarez Herrero, Lorenza, Bogte, Auke, Alkhalaf, Alaa, Schenk, B. Ed, Koch, Arjun D., Spaander, Manon C.W., Tang, Thjon J., Nagengast, Wouter B., Westerhof, Jessie, Houben, Martin H.M.G., Bergman, Jacques J.G.H.M., Schoon, Erik J., and Pouw, Roos E.

Published
2022

39. Wide-area transepithelial sampling with computer-assisted analysis to detect high grade dysplasia and cancer in Barrettʼs esophagus: A Multi-Center, Randomized Study

Author

MS MDL 1, Cancer, Van Munster, Sanne, Leclercq, Philippe, Haidry, Rehan, Messmann, Helmut, Probst, Andreas, Ragunath, Krish, Bhandari, Pradeep, Repici, Alessandro, Munoz-Navas, Miguel, Seewald, Stefan, Lemmers, Arnaud, Fernández-Esparrach, Glòria, Pech, Oliver, Schoon, Erik J., Kariv, Revital, Neuhaus, Horst, Weusten, Bas L.A.M., Siersema, Peter D., Correale, Loredana, Meijer, Sybren L., De Hertogh, Gert, Bergman, Jacques Jghm, Hassan, Cesare, Bisschops, Raf, MS MDL 1, Cancer, Van Munster, Sanne, Leclercq, Philippe, Haidry, Rehan, Messmann, Helmut, Probst, Andreas, Ragunath, Krish, Bhandari, Pradeep, Repici, Alessandro, Munoz-Navas, Miguel, Seewald, Stefan, Lemmers, Arnaud, Fernández-Esparrach, Glòria, Pech, Oliver, Schoon, Erik J., Kariv, Revital, Neuhaus, Horst, Weusten, Bas L.A.M., Siersema, Peter D., Correale, Loredana, Meijer, Sybren L., De Hertogh, Gert, Bergman, Jacques Jghm, Hassan, Cesare, and Bisschops, Raf

Published
2022

40. Barrett Esophagus: Quality of life and factors associated with illness perception

Author

MS MDL 1, Cancer, van der Ende-van Loon, Mirjam C.M., Nieuwkerk, Pythia T., van Stiphout, Stephan H.C., Scheffer, Robert C.H., de Ridder, Rogier J.J., Pouw, Roos E., Alkhalaf, Alaa, Weusten, Bas L.A.M., Curvers, Wouter L., Schoon, Erik J., MS MDL 1, Cancer, van der Ende-van Loon, Mirjam C.M., Nieuwkerk, Pythia T., van Stiphout, Stephan H.C., Scheffer, Robert C.H., de Ridder, Rogier J.J., Pouw, Roos E., Alkhalaf, Alaa, Weusten, Bas L.A.M., Curvers, Wouter L., and Schoon, Erik J.

Published
2022

42. Dysplastic Recurrence After Successful Treatment for Early Barrett's Neoplasia: Development and Validation of a Prediction Model

Author

MS MDL 1, Cancer, Infection & Immunity, JC onderzoeksprogramma Methodologie, JC onderzoeksprogramma Infectieziekten, Circulatory Health, Child Health, Biostatistiek Onderzoek, Julius Centrum, van Munster, Sanne N., Nieuwenhuis, Esther, Bisschops, Raf, Willekens, Hilde, Weusten, Bas L.A.M., Herrero, Lorenza Alvarez, Bogte, Auke, Alkhalaf, Alaa, Schenk, Ed B.E., Schoon, Erik J., Curvers, Wouter, Koch, Arjun D., de Jonge, Pieter Jan F., Tang, Tjon J., Nagengast, Wouter B., Westerhof, Jessie, Houben, Martin H.M.G., Seewald, Stefan, Eijkemans, Martinus J.C., Bergman, Jacques J.G.H.M., Pouw, Roos E., MS MDL 1, Cancer, Infection & Immunity, JC onderzoeksprogramma Methodologie, JC onderzoeksprogramma Infectieziekten, Circulatory Health, Child Health, Biostatistiek Onderzoek, Julius Centrum, van Munster, Sanne N., Nieuwenhuis, Esther, Bisschops, Raf, Willekens, Hilde, Weusten, Bas L.A.M., Herrero, Lorenza Alvarez, Bogte, Auke, Alkhalaf, Alaa, Schenk, Ed B.E., Schoon, Erik J., Curvers, Wouter, Koch, Arjun D., de Jonge, Pieter Jan F., Tang, Tjon J., Nagengast, Wouter B., Westerhof, Jessie, Houben, Martin H.M.G., Seewald, Stefan, Eijkemans, Martinus J.C., Bergman, Jacques J.G.H.M., and Pouw, Roos E.

Published
2022

43. Development and External Validation of a Model to Predict Complex Treatment After Radiofrequency Ablation for Barrett's Esophagus With Early Neoplasia

Author

MS MDL 1, Cancer, van Munster, Sanne N., Nieuwenhuis, Esther, Bisschops, Raf, Willekens, Hilde, Weusten, Bas L.A.M., Herrero, Lorenza Alvarez, Bogte, Auke, Alkhalaf, Alaa, Schenk, Ed B.E., Schoon, Erik J., Curvers, Wouter, Koch, Arjun D., de Jonge, Pieter Jan F., Tang, Tjon J., Nagengast, Wouter B., Westerhof, Jessie, Houben, Martin H.M.G., Bergman, Jacques J.G.H.M., Pouw, Roos E., MS MDL 1, Cancer, van Munster, Sanne N., Nieuwenhuis, Esther, Bisschops, Raf, Willekens, Hilde, Weusten, Bas L.A.M., Herrero, Lorenza Alvarez, Bogte, Auke, Alkhalaf, Alaa, Schenk, Ed B.E., Schoon, Erik J., Curvers, Wouter, Koch, Arjun D., de Jonge, Pieter Jan F., Tang, Tjon J., Nagengast, Wouter B., Westerhof, Jessie, Houben, Martin H.M.G., Bergman, Jacques J.G.H.M., and Pouw, Roos E.

Published
2022

44. Long-term outcomes after endoscopic treatment for Barrett's neoplasia with radiofrequency ablation ± endoscopic resection: Results from the national Dutch database in a 10-year period

Author

MS MDL 1, Cancer, Van Munster, Sanne, Nieuwenhuis, Esther, Weusten, Bas L.A.M., Alvarez Herrero, Lorenza, Bogte, Auke, Alkhalaf, Alaa, Schenk, B. E., Schoon, Erik J., Curvers, Wouter, Koch, Arjun D., Van De Ven, Steffi Elisabeth Maria, De Jonge, Pieter Jan Floris, Tang, Tjon J., Nagengast, Wouter B., Peters, Frans T.M., Westerhof, Jessie, Houben, Martin H.M.G., Bergman, Jacques J.G.H.M., Pouw, Roos E., MS MDL 1, Cancer, Van Munster, Sanne, Nieuwenhuis, Esther, Weusten, Bas L.A.M., Alvarez Herrero, Lorenza, Bogte, Auke, Alkhalaf, Alaa, Schenk, B. E., Schoon, Erik J., Curvers, Wouter, Koch, Arjun D., Van De Ven, Steffi Elisabeth Maria, De Jonge, Pieter Jan Floris, Tang, Tjon J., Nagengast, Wouter B., Peters, Frans T.M., Westerhof, Jessie, Houben, Martin H.M.G., Bergman, Jacques J.G.H.M., and Pouw, Roos E.

Published
2022

45. Novel cryoballoon 180 degrees ablation system for treatment of Barrett's esophagus-related neoplasia: a first-in-human study: A first-in-human study

Author

MS MDL 1, Cancer, Overwater, Anouk, Van Munster, Sanne N., Nagengast, Wouter B., Pouw, Roos E., Bergman, Jacques J.G.H.M., Schoon, Erik J., Weusten, Bas L.A.M., MS MDL 1, Cancer, Overwater, Anouk, Van Munster, Sanne N., Nagengast, Wouter B., Pouw, Roos E., Bergman, Jacques J.G.H.M., Schoon, Erik J., and Weusten, Bas L.A.M.

Published
2022

47. Higher quality of life after metal stent placement compared with plastic stent placement for malignant extrahepatic bile duct obstruction: a randomized controlled trial

Author

Walter, Daisy, van Boeckel, Petra G.A., Groenen, Marcel J.M., Weusten, Bas L.A.M., Witteman, Ben J., Tan, Gi, Brink, Menno A., Nicolai, Jan, Tan, Adriaan C., Alderliesten, Joyce, Venneman, Niels G., Laleman, Wim, Jansen, Jeroen M., Bodelier, Alexander, Wolters, Frank L., van der Waaij, Laurens A., Breumelhof, Ronald, Peters, Frans T.M., Scheffer, Robbert C.H., Steyerberg, Ewout W., May, Anne M., Leenders, Max, Hirdes, Meike M.C., Vleggaar, Frank P., and Siersema, Peter D.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results